BRIEF-Pharming Group announces positive results from a phase 2 clinical study of RUCONEST
July 18 (Reuters) - Pharming Group NV
* Announced positive results from a phase 2 clinical study of RUCONEST
* Announces positive results from randomized controlled trial with RUCONEST for HAE Prophylaxis
* Pharming will receive an undisclosed milestone payment from Valeant as and when FDA approval for this additional indication is given Source text for Eikon: Further company coverage: (Gdynia Newsroom)
© Thomson Reuters 2017 All rights reserved.